Jason Rhodes is a partner at Atlas Venture and focuses on creating and building novel therapeutics companies.

He is the chairman and was the founding CEO of Dyne Therapeutics (NASDAQ: DYN) and was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly. He was previously an executive with Alnylam (NASDAQ: ALNY) and a partner with F-Prime, the biotech venture arm of Fidelity Investments, where he led the investment in FoldRx, the inventor and developer of Tafamadis, acquired by Pfizer.